Preconceived notions about biosimilars—a French experience
Résumé
Since the arrival of the first biosimilar monoclonal antibodies into the market, many information has been circulating, leading to
preconceived notions for patients and healthcare professionals. In a pressing economic context and faced with a growing number
of available biosimilars, we (clinician, patient association, biologist, pharmacists, health economists) propose to take stock by
trying to distinguish facts from misconceptions.